AGIOS PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.15M, a 4744.62% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.08M, a 28.35% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $4.43M, a 68.18% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $65.00K, a 94.09% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $8.68M, a 39.93% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $14.44M, a 165.82% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $5.43M, a 102.65% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $2.68M, a 92.81% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.15M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $2.08M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $8.68M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $4.43M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $65.00K 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $1.62M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $14.44M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $2.64M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $1.10M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $5.86M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $5.43M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $1.88M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $238.00K 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $2.47M 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $2.68M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $1.27M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $15.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $1.29M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $37.30M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $4.01M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $25.67M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $7.35M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $11.32M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $3.53M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.65M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $5.46M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $12.52M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $3.23M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $2.77M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $6.00M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $30.22M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $7.26M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $9.64M 10-Q · filed 2019-10-31 | |
| 2018-03-31 | $12.33M 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $14.19M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $7.70M 10-K · filed 2019-02-14 | |
| 2015-12-31 | $7.14M 10-K · filed 2018-02-14 | |
| 2014-12-31 | $2.32M 10-K · filed 2017-02-16 | |
| 2013-12-31 | $150.00K 10-K · filed 2016-02-26 | |
| 2012-12-31 | $87.00K 10-K · filed 2015-02-24 | |
| 2011-12-31 | $57.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |